Abdominal aortic aneurysm medical therapy
|
Abdominal Aortic Aneurysm Microchapters |
|
Differentiating Abdominal Aortic Aneurysm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Abdominal aortic aneurysm medical therapy On the Web |
|
Directions to Hospitals Treating Abdominal aortic aneurysm medical therapy |
|
Risk calculators and risk factors for Abdominal aortic aneurysm medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Aarti Narayan, M.B.B.S [3]
Medical therapy
Management
- Risk factor modification
- Smoking cessation
- ACEI, beta blockers, statins, aspirin, antibiotics for possible chlamydia infection
- Assess for coronary, carotid and peripheral vascular disease
- Surveillance:
- 4 to 5.4 cm - monitor every 6 to 12 months
- 3 to 4 cm - monitor every 2 to 3 years
Acute pharmacotherapies
- Antimetalloproteases such as doxycycline and roxithromycin may halt aneurysm expansion
- Similarly, non-steriod anti inflammatory drugs have shown to be beneficial in small studies
- Beta blockers have numerous benefits in patients with cardiovascular disease
- Reduce aortic complications in patients with Marfan syndrome
- Slow progression of AAAs in hypertensive patients
- In the absence of other indications for beta blockers, the evidence is insufficient to recommend using them routinely for the sole purpose of slowing atherosclerotic aneurysm growth